Diagnostic yield of a heart failure referral pathway using N-terminal pro-brain natriuretic peptide
Author
Zegard, AbbasinNaneishvili, Tamara
Viyapurapu, Ravi
Desai, Purushottam
White, Sam
Patel, Peysh A
Stegemann, Berthold
Zaphiriou, Alex
Qiu, Tian
Leyva, Francisco
Affiliation
Aston University; University Hospitals Birmingham NHS Foundation TrustPublication date
2023-10Subject
Cardiology
Metadata
Show full item recordAbstract
Objective: To determine the diagnostic yield of a 'high' N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with suspected heart failure (HF) referred from primary to secondary care. Methods: In this retrospective study, cardiac diagnoses were quantified in consecutive patients with an NT-proBNP>400 ng/L referred from primary care centres to a specialist HF service. Results: Among 654 consecutive patients (age: 78.5±9.72 years; 45.9% men; left ventricular ejection fraction (LVEF): 55.4±12.5% (mean±SD)), the primary diagnoses were: valvular disease (39.4%), HF (29.2%; 13.3% with LVEF<40%) and atrial fibrillation (AF; 17.3%). In terms of primary or secondary diagnoses, 68% of patients had valve disease, 46.9% had AF and 29.2% had HF. A cardiac diagnosis was made in 85.9%. In multivariable analyses, NT-proBNP predicted HF with LVEF<40% (OR: 10.2, 95% CI: 5.63 to 18.3) and HF with any LVEF (OR: 6.13, 95% CI: 3.79 to 9.93). In canonical linear discriminant analyses, NT-proBNP correctly identified 54.5% of patients with HF. The remainder were misclassified as valvular disease, AF or no cardiac diagnosis. Conclusion: Among patients with an NT-proBNP>400 ng/L referred through a primary care HF pathway, most patients had valve disease or AF rather than HF. NT-proBNP cannot discriminate among HF, valve disease and AF. On this basis, NT-proBNP may be best employed in detecting cardiac disease in general rather than HF per se.Citation
Zegard A, Naneishvili T, Viyapurapu R, Desai P, White S, Patel PA, Stegemann B, Zaphiriou A, Qiu T, Leyva F. Diagnostic yield of a heart failure referral pathway using N-terminal pro-brain natriuretic peptide. Open Heart. 2023 Oct;10(2):e002469. doi: 10.1136/openhrt-2023-002469.Type
ArticleAdditional Links
http://openheart.bmj.com/PMID
37793674Journal
Open HeartPublisher
BMJ Publishing Groupae974a485f413a2113503eed53cd6c53
10.1136/openhrt-2023-002469